Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-1544
Abstract: Purpose: Preoperative aromatase inhibitor (AI) therapy has demonstrated efficacy in hormone receptor (HR)-positive postmenopausal breast cancer. However, many patients have disease that is either intrinsically resistant to AIs or that responds initially but develops resistance… read more here.
Keywords: positive tumors; breast cancer; cytoplasmic cyclin; mediates resistance ... See more keywords
Rovalpituzumab Tesirine Is Active in Patients with DLL3-Positive Tumors.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2016-232
Abstract: Rovalpituzumab tesirine is well tolerated and has single-agent antitumor activity. read more here.
Keywords: patients dll3; positive tumors; rovalpituzumab tesirine; dll3 positive ... See more keywords